Spike-Binding Small Molecules for Broad-Spectrum Viral Entry Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-viral treatments for viral infections, such as COVID-19, are limited in availability, effectiveness, and cost, and there is a need for rapid, broad-spectrum antiviral agents that can block virus entry into cells, particularly for high-risk populations and immunocompromised individuals.
Innovation Solution
Development of small molecules, such as CD04872SC, that bind to the Spike protein of SARS-CoV-2 and its variants, disrupting the interaction with the ACE2 receptor to prevent viral entry into cells, administered through various routes including nasal sprays and aerosols.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-viral treatments are used, then viral infections can be treated, but availability and cost are limited
Solution Approach 1:
The small molecule compounds are designed to target conserved regions of viral proteins (such as the spike protein receptor-binding domain) that are common across multiple virus variants including SARS-CoV-2, Delta, and Omicron. This allows a single compound to provide broad-spectrum protection against different viral strains and mutations, addressing the limitation of current treatments that are often variant-specific.
Solution Approach 2:
The invention employs high-throughput screening to identify compounds with optimized binding affinity and specificity parameters for viral targets. By systematically varying chemical structures and screening large compound libraries, the methodology discovers molecules with enhanced efficacy across multiple virus types while maintaining favorable pharmacological properties for human use.
2Loss of time
If small molecules like CD04872SC are developed to block virus entry, then immediate protection can be provided, but rapid development and screening are required
Solution Approach 1:
The invention uses computational modeling and in silico screening to pre-identify promising compound candidates before conducting expensive and time-consuming wet-lab experiments. By predicting which molecules are most likely to bind effectively to viral targets, the methodology accelerates the discovery process and reduces the time required to develop protective agents.
Solution Approach 2:
The invention replaces traditional slow, trial-and-error experimental screening with automated high-throughput screening systems and computational algorithms. This substitution of mechanical/experimental methods with automated and computational approaches dramatically increases screening productivity, allowing evaluation of thousands of compounds in parallel to identify effective antivirals more rapidly.
3Object-affected harmful factors
If compounds are designed to bind to Spike protein and disrupt ACE2 interaction, then virus entry can be blocked, but specificity and minimal cytotoxicity must be maintained
Solution Approach 1:
The small molecule compounds act as molecular intermediaries that bind to the spike protein's receptor-binding domain and physically block the interaction between the virus and host ACE2 receptors. These intermediary molecules prevent direct virus-receptor contact while maintaining cell membrane integrity and normal cellular functions, thereby achieving antiviral effect without cytotoxicity.
Solution Approach 2:
The compounds are designed to specifically target and bind to the local region of the spike protein involved in ACE2 recognition (the receptor-binding domain). By concentrating their antiviral activity at this specific local site rather than affecting entire cells or multiple protein domains, the molecules achieve high antiviral specificity while minimizing off-target effects and cytotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CD04872SC effectively inhibits SARS-CoV-2, Delta, and Omicron infections in vitro with minimal cytotoxicity, providing immediate protection and potential treatment for COVID-19, especially for high-risk populations.
Implementation Method 1
small molecules, such as CD04872SC, that bind to the Spike protein of SARS-CoV-2 and its variants, disrupting the interaction with the ACE2 receptor to prevent viral entry into cells
Data Source
AI summary
The invention relates to anti-viral compounds suitable for use in blocking virus entry into cells, and methods of blocking virus entry into cells by associating the cells with the anti-viral compounds. The associating may occur in vitro, or in vivo in a subject through administration of the anti-viral compounds to the subject. The invention also relates to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound. The subject may be a human being suffering from or vulnerable to the viral infection. The virus may include a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2).